In a latest study, the researchers at Vanderbilt University have found that the use of non-steroidal anti-inflammatory drugs like aspirin is significantly associated with lower PSA (prostate-specific antigen) levels and may drop the prostate cancer risk.

The research was conducted upon 1,277 people referred to a urologist for a biopsy of their prostate. Approximately 46 per cent of them reported taking an NSAID, mostly aspirin (37 per cent of all men). After taking into account age, race, family prostate cancer history, obesity, and other variables, the researchers found that PSA levels were 9 per cent lower in men taking aspirin compared with men who did not use aspirin.

The study will be presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research.